{"id":55609,"date":"2023-04-06T23:05:36","date_gmt":"2023-04-06T21:05:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/"},"modified":"2023-04-06T23:05:36","modified_gmt":"2023-04-06T21:05:36","slug":"firsthand-technology-value-fund-discloses-top-portfolio-holdings","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/","title":{"rendered":"Firsthand Technology Value Fund Discloses Top Portfolio Holdings"},"content":{"rendered":"
\n

SAN JOSE, Calif.–(BUSINESS WIRE)–Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the \u201cFund\u201d), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of February 28, 2023, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital.<\/p>\n

<\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n
\n

\n1.<\/p>\n<\/td>\n

<\/td>\n\n

\nIntraOp Medical Corp.<\/b> is the manufacturer of the Mobetron, a medical device that is used to deliver intra-operative radiation to cancer patients. As of February 28, 2023, the Fund\u2019s investment in IntraOp consisted of preferred stock plus debt securities and represented approximately 39.3% of the Fund\u2019s estimated total investments.*<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\n2.<\/p>\n<\/td>\n

<\/td>\n\n

\nWrightspeed, Inc. <\/b>is a supplier of electric drivetrains for heavy-duty commercial vehicles. As of February 28, 2023, the Fund\u2019s investment in Wrightspeed consisted of preferred stock plus debt securities and warrants to purchase additional shares and represented approximately 20.6% of the Fund\u2019s estimated total investments.*<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\n3.<\/p>\n<\/td>\n

<\/td>\n\n

\nHera Systems, Inc.<\/b> is developing micro satellites with imaging and communication capabilities for launch into low Earth orbit. As of February 28, 2023, the Fund\u2019s investment in Hera consisted of preferred stock plus debt securities and warrants to purchase additional shares and represented approximately 18.1% of the Fund\u2019s estimated total investments.*<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\n4.<\/p>\n<\/td>\n

<\/td>\n\n

\nRevasum, Inc. (ASX: RVS) <\/b>is a provider of chemical-mechanical planarization (CMP) and grinding tools to the semiconductor industry. As of February 28, 2023, the Fund\u2019s investment in Revasum consisted of common stock equivalents (CDIs) and represented approximately 16.6% of the Fund\u2019s estimated total investments.*<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\n5.<\/p>\n<\/td>\n

<\/td>\n\n

\nEQX Capital, Inc. <\/b>provides equipment financing solutions to technology companies and their customers. As of February 28, 2023, the Fund\u2019s investment in EQX consisted of preferred and common stock and represented approximately 2.0% of the Fund\u2019s estimated total investments.*<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nThe Fund also announced that as of February 28, 2023, the estimated total investments* of the Fund were approximately $42.5 million, or $6.32 per share, including cash and cash equivalents of approximately $0.15 per share. As of that date, the Fund\u2019s top five holdings constituted 96.6% of the Fund\u2019s estimated total investments.* Complete financial statements and a detailed schedule of investments as of March 31, 2023, will be available in the Fund\u2019s quarterly report filing on Form 10-Q in May 2023.<\/p>\n

\n*Total investments are estimated as of February 28, 2023, and represent the value of the Fund\u2019s total investments as of December 31, 2022, plus the estimated net change in unrealized appreciation\/depreciation and actual realized gains\/losses on publicly traded and private securities since December 31, 2022. For the purposes of calculating the percentage of estimated total investments represented by each investment, the value of each holding is determined by either: (1) the purchase price, (2) the market value for public securities, less any discounts taken due to restrictions on the stock, or (3) the December 31, 2022, fair value of each security, as determined under procedures approved by our Board of Directors. The estimated total investments figure does not reflect net asset value because actual and estimated liabilities (such as estimated tax liabilities and performance fees, accrued vendor service fees and other liabilities) are not deducted.<\/p>\n

\nAbout Firsthand Technology Value Fund<\/b><\/p>\n

\nFirsthand Technology Value Fund, Inc. is a publicly traded venture capital fund that invests in technology and cleantech companies. More information about the Fund and its holdings can be found online at www.firsthandtvf.com<\/a>.<\/p>\n

\nThe Fund is a non-diversified, closed-end investment company that elected to be treated as a business development company under the Investment Company Act of 1940. The Fund\u2019s investment objective is to seek long-term growth of capital. Under normal circumstances, the Fund will invest at least 80% of its total assets for investment purposes in technology and cleantech companies. An investment in the Fund involves substantial risks, some of which are highlighted below. Unlike most business development companies, the Fund is taxed as a corporation rather than a Regulated Investment Company under federal tax laws, based on the composition of its assets. Please see the Fund\u2019s public filings for more information about fees, expenses and risk. Past investment results do not provide any assurances about future results.<\/i><\/p>\n

\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains “forward-looking statements” as defined under the U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will,” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to materially differ from the Fund\u2019s historical experience and its present expectations or projections indicated in any forward-looking statement. These risks include, but are not limited to, changes in economic and political conditions, regulatory and legal changes, technology and cleantech industry risk, valuation risk, non-diversification risk, interest rate risk, tax risk, and other risks discussed in the Fund\u2019s filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Fund undertakes no obligation to publicly update or revise any forward-looking statements made herein. There is no assurance that the Fund\u2019s investment objectives will be attained. We acknowledge that, notwithstanding the foregoing, the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995 does not apply to investment companies such as us.<\/i><\/p>\n

Contacts<\/b> <\/p>\n

\nPhil Mosakowski
\n
Firsthand Capital Management, Inc.
\n
(408) 624-9526
\n
vc@firsthandtvf.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN JOSE, Calif.–(BUSINESS WIRE)–Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the \u201cFund\u201d), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of February 28, 2023, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital. 1. IntraOp Medical Corp. is the manufacturer of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55609","6":"format-standard","7":"category-industry"},"yoast_head":"\nFirsthand Technology Value Fund Discloses Top Portfolio Holdings - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Firsthand Technology Value Fund Discloses Top Portfolio Holdings - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN JOSE, Calif.–(BUSINESS WIRE)–Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the \u201cFund\u201d), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of February 28, 2023, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital. 1. IntraOp Medical Corp. is the manufacturer of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-06T21:05:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230406005664\/en\/1758415\/21\/firsthandlogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Firsthand Technology Value Fund Discloses Top Portfolio Holdings\",\"datePublished\":\"2023-04-06T21:05:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/\"},\"wordCount\":865,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230406005664\\\/en\\\/1758415\\\/21\\\/firsthandlogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/\",\"name\":\"Firsthand Technology Value Fund Discloses Top Portfolio Holdings - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230406005664\\\/en\\\/1758415\\\/21\\\/firsthandlogo.jpg\",\"datePublished\":\"2023-04-06T21:05:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230406005664\\\/en\\\/1758415\\\/21\\\/firsthandlogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230406005664\\\/en\\\/1758415\\\/21\\\/firsthandlogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Firsthand Technology Value Fund Discloses Top Portfolio Holdings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Firsthand Technology Value Fund Discloses Top Portfolio Holdings - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/","og_locale":"en_US","og_type":"article","og_title":"Firsthand Technology Value Fund Discloses Top Portfolio Holdings - Pharma Trend","og_description":"SAN JOSE, Calif.–(BUSINESS WIRE)–Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the \u201cFund\u201d), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of February 28, 2023, were IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital. 1. IntraOp Medical Corp. is the manufacturer of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-06T21:05:36+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230406005664\/en\/1758415\/21\/firsthandlogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Firsthand Technology Value Fund Discloses Top Portfolio Holdings","datePublished":"2023-04-06T21:05:36+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/"},"wordCount":865,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230406005664\/en\/1758415\/21\/firsthandlogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/","url":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/","name":"Firsthand Technology Value Fund Discloses Top Portfolio Holdings - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230406005664\/en\/1758415\/21\/firsthandlogo.jpg","datePublished":"2023-04-06T21:05:36+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230406005664\/en\/1758415\/21\/firsthandlogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230406005664\/en\/1758415\/21\/firsthandlogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/firsthand-technology-value-fund-discloses-top-portfolio-holdings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Firsthand Technology Value Fund Discloses Top Portfolio Holdings"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55609"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55609\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}